Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT

Published date: 16 June 2021

Additional Information: Funding Information: Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 38. See the NIHR Journals Library website for further project information. Funding Information: Declared competing interests of authors: Philip Hykin has received grants, personal fees and nonfinancial support from Bayer AG (Leverkusen, Germany), Novartis International AG (Basel, Switzerland) and Allergan plc (Dublin, Ireland). A Toby Prevost was a member of the National Institute for Health Research (NIHR) Public Health Research Committee (June 2014–June 2020) and is a member of the NIHR COVID Call (Recovery and Learning) Committee (June 2020–present); he has received a lecture fee from Bayer AG and a grant from Boehringer Ingelheim (Ingelheim, Germany). Sobha Sivaprasad is part of the NIHR Health Technology Assessment (HTA) Commissioning Board (31 July 2017–present) and has received personal fees and grants from Novartis International AG, Bayer AG, Allergan plc and Boehringer Ingelheim, personal fees from F. Hoffmann-La Roche AG (Basel, Switzerland), personal fees and non-financial support from Optos plc (Marlborough, MA, USA) and personal fees from Heidelberg Engineering Inc. (Franklin, MA, USA). Laura Flight has received grants from NIHR for her NIHR Doctoral Fellowship, Adaptive Design Clinical Trials and their Impact on the Economic Evaluation of Health Care Technologies (DRF-2015-08-013), and another NIHR project, Value-based Adaptive Clinical Trial Designs for Efficient Delivery of NIHR Research (NIHR130354). Rebekah Pennington has received research grants from F. Hoffmann-La Roche AG. Yit Yang has received personal fees and non-financial support from Novartis International AG, Bayer AG and personal fees from Allergan plc and F. Hoffmann-La Roche AG. Simon P Harding has received grants to his employer from the NIHR HTA Clinical Evaluation and Trials UK and F. Hoffmann-La Roche AG. Andrew Lotery has received travel support from Bayer AG, and personal fees from Novartis International AG and Allergan plc. Usha Chakravarthy has received grants from NIHR [for the Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN) trial, 07/36/01], was part of the HTA Prioritisation Committee (2010–14) and has received personal fees from Allergan plc and Novartis International AG. Funding Information: Declared competing interests of authors: Philip Hykin has received grants, personal fees and non-financial support from Bayer AG (Leverkusen, Germany), Novartis International AG (Basel, Switzerland) and Allergan plc (Dublin, Ireland). A Toby Prevost was a member of the National Institute for Health Research (NIHR) Public Health Research Committee (June 2014?June 2020) and is a member of the NIHR COVID Call (Recovery and Learning) Committee (June 2020?present); he has received a lecture fee from Bayer AG and a grant from Boehringer Ingelheim (Ingelheim, Germany). Sobha Sivaprasad is part of the NIHR Health Technology Assessment (HTA) Commissioning Board (31 July 2017?present) and has received personal fees and grants from Novartis International AG, Bayer AG, Allergan plc and Boehringer Ingelheim, personal fees from F. Hoffmann-La Roche AG (Basel, Switzerland), personal fees and non-financial support from Optos plc (Marlborough, MA, USA) and personal fees from Heidelberg Engineering Inc. (Franklin, MA, USA). Laura Flight has received grants from NIHR for her NIHR Doctoral Fellowship, Adaptive Design Clinical Trials and their Impact on the Economic Evaluation of Health Care Technologies (DRF-2015-08-013), and another NIHR project, Value-based Adaptive Clinical Trial Designs for Efficient Delivery of NIHR Research (NIHR130354). Rebekah Pennington has received research grants from F. Hoffmann-La Roche AG. Yit Yang has received personal fees and non-financial support from Novartis International AG, Bayer AG and personal fees from Allergan plc and F. Hoffmann-La Roche AG. Simon P Harding has received grants to his employer from the NIHR HTA Clinical Evaluation and Trials UK and F. Hoffmann-La Roche AG. Andrew Lotery has received travel support from Bayer AG, and personal fees from Novartis International AG and Allergan plc. Usha Chakravarthy has received grants from NIHR [for the Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN) trial, 07/36/01], was part of the HTA Prioritisation Committee (2010?14) and has received personal fees from Allergan plc and Novartis International AG.Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 38. See the NIHR Journals Library website for further project information. Funding Information: This project was funded by the NIHR HTA Clinical Evaluation and Trials programme (number 11/92/03). The trial was sponsored by the NIHR Moorfields Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust. The research was supported by the NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and the University College London Institute of Ophthalmology, the UK Clinical Research Collaboration-registered KCTU at King’s Health Partners, which is part-funded by the NIHR Maudsley Biomedical Research Centre, at South London and Maudsley NHS Foundation Trust, and King’s College London. Funding Information: The research reported in this issue of the journal was funded by the HTA programme as project number 11/92/03. The contractual start date was in June 2014. The draft report began editorial review in August 2019 and was accepted for publication in June 2020. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report. Publisher Copyright: © Queen’s Printer and Controller of HMSO 2021. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

Local EPrints ID: 453451

URI: http://eprints.soton.ac.uk/id/eprint/453451

DOI: doi:10.3310/HTA25380

ISSN: 1366-5278

PURE UUID: b415f61d-f42d-4578-8d2e-31ecb256106d

ORCID for Andrew Lotery: orcid.org/0000-0001-5541-4305

Date deposited: 17 Jan 2022 17:47

Last modified: 18 Mar 2024 02:57